In early 2021, the United States Senate Finance Committee released a report examining the factors that have led to the significant rise in Insulin drug prices over the course of the 21st century. This paper summarizes the key findings from the Committee report and describes the motivations and outcomes for the main stakeholders in the U.S. pharmaceutical supply chain.
